focus -WSS

focus

author：explore 2025-09-06 02:04:49 - browse：7

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 4th of July breaks record for highest global temperature ever measured

WSS

RaDonda Vaught case: a double standard for nurses, physicians

Multiple sclerosis has subtypes with different best treatments: study

Oral obesity drug from Viking Therapeutics hits key early target

People with mental disorders often marry others with same

Study: Black kids more likely to die after surgery than white kids

Four alarming medical procedures we’re glad history forgot

knowledge

focus

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Sports medicine is finally prioritizing gender equality

Hundreds died while taking an arthritis drug, but nobody alerted patients

Bright Health sells Medicare Advantage business to Molina

7 people shot in DC, police say

Hepatitis C has a cure — but many Americans still lack access to it

Scientists uncover potential path to treating deadly childhood tumor

Sports medicine is finally prioritizing gender equality

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

focus

Pancreatic cancer is often deadly, but new discoveries are raising hope

Researchers test human milk's ability to repair gut microbiome

Meta looks to target Twitter with a rival app called Threads

Option Care buys Amedisys in $3.6 billion home care deal

Grail is spending more than ever lobbying Congress

Insurer loopholes limit power of law against surprise medical bills

focus

leisure time

explore

focus